TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial to Evaluate the Impact of Using a Point-of-care Urine LAM Strip Test for TB Diagnosis Amongst Hospitalized HIV-infected Patients in Resource-poor Settings
Brief Summary: The novel urine LAM point-of-care strip test offers potential clinical utility to improve TB diagnosis in HIV co-infected patients. Urine LAM strip test performance improves with increasing illness severity and more advanced immunosuppression, thus offering the greatest potential utility in hospitalised HIV-infected patients with advanced immunosuppression (CD4 cell count less than 200). However, in the context of high rates of empiric treatment and the availability of other novel TB diagnostics, the clinical impact of the urine LAM strip test is unknown. This study will investigate the impact of the urine LAM strip test. The study hypothesis is that the urine LAM strip test, when combined with standard TB diagnostics (smear microscopy and culture) will significantly improve TB treatment-related outcomes (TB-related mortality, morbidity and length of hospital stay) in HIV-infected hospitalized patients when compared to standard TB diagnostics alone.


Options:
A: Arm Label: LAM plus standard care; Type: EXPERIMENTAL; Interventions: Device: Urine LAM strip test | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Urine LAM strip test; Assigned to Arm(s): LAM plus standard care
B: Intervention Type: OTHER; Name: Development of a diagnosis algorithm; Assigned to Arm(s): N/A
C: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Interventional; Type: EXPERIMENTAL; Interventions: Diagnostic Test: Xpert MTB/RIF Ultra (Ultra) | Intervention Type: DIAGNOSTIC_TEST; Name: Xpert MTB/RIF Ultra (Ultra); Assigned to Arm(s): Interventional
D: Arm Label: Urgent ART; Type: EXPERIMENTAL; Interventions: Other: Urgent ART | Arm Label: Early ART; Type: ACTIVE_COMPARATOR; Interventions: Other: Early ART | Intervention Type: OTHER; Name: Urgent ART; Assigned to Arm(s): Urgent ART | Intervention Type: OTHER; Name: Early ART; Assigned to Arm(s): Early ART

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial to Evaluate the Impact of Using a Point-of-care Urine LAM Strip Test for TB Diagnosis Amongst Hospitalized HIV-infected Patients in Resource-poor Settings
Brief Summary: The novel urine LAM point-of-care strip test offers potential clinical utility to improve TB diagnosis in HIV co-infected patients. Urine LAM strip test performance improves with increasing illness severity and more advanced immunosuppression, thus offering the greatest potential utility in hospitalised HIV-infected patients with advanced immunosuppression (CD4 cell count less than 200). However, in the context of high rates of empiric treatment and the availability of other novel TB diagnostics, the clinical impact of the urine LAM strip test is unknown. This study will investigate the impact of the urine LAM strip test. The study hypothesis is that the urine LAM strip test, when combined with standard TB diagnostics (smear microscopy and culture) will significantly improve TB treatment-related outcomes (TB-related mortality, morbidity and length of hospital stay) in HIV-infected hospitalized patients when compared to standard TB diagnostics alone.


Options:
A: Intervention Type: DEVICE; Name: Alere "Determine" lateral-flow urine lipoarabinomannan assay; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Alere "Clearview" ELISA urine LAM assay; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Cepheid Xpert MTB/Rif assay; Assigned to Arm(s): N/A
B: Arm Label: LAM plus standard care; Type: EXPERIMENTAL; Interventions: Device: Urine LAM strip test | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Urine LAM strip test; Assigned to Arm(s): LAM plus standard care
C: N/A
D: Intervention Type: DEVICE; Name: Alere "Determine" lateral-flow urine lipoarabinomannan assay; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Alere "Clearview" ELISA urine LAM assay; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial to Evaluate the Impact of Using a Point-of-care Urine LAM Strip Test for TB Diagnosis Amongst Hospitalized HIV-infected Patients in Resource-poor Settings
Brief Summary: The novel urine LAM point-of-care strip test offers potential clinical utility to improve TB diagnosis in HIV co-infected patients. Urine LAM strip test performance improves with increasing illness severity and more advanced immunosuppression, thus offering the greatest potential utility in hospitalised HIV-infected patients with advanced immunosuppression (CD4 cell count less than 200). However, in the context of high rates of empiric treatment and the availability of other novel TB diagnostics, the clinical impact of the urine LAM strip test is unknown. This study will investigate the impact of the urine LAM strip test. The study hypothesis is that the urine LAM strip test, when combined with standard TB diagnostics (smear microscopy and culture) will significantly improve TB treatment-related outcomes (TB-related mortality, morbidity and length of hospital stay) in HIV-infected hospitalized patients when compared to standard TB diagnostics alone.


Options:
A: Arm Label: LAM plus standard care; Type: EXPERIMENTAL; Interventions: Device: Urine LAM strip test | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Urine LAM strip test; Assigned to Arm(s): LAM plus standard care
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Interventional; Type: EXPERIMENTAL; Interventions: Diagnostic Test: Xpert MTB/RIF Ultra (Ultra) | Intervention Type: DIAGNOSTIC_TEST; Name: Xpert MTB/RIF Ultra (Ultra); Assigned to Arm(s): Interventional
C: Arm Label: Xpert MTB/RIF; Type: EXPERIMENTAL; Interventions: Procedure: Xpert MTB/RIF assay | Arm Label: Sputum smear microscopy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Smear microscopy | Intervention Type: PROCEDURE; Name: Xpert MTB/RIF assay; Assigned to Arm(s): Xpert MTB/RIF | Intervention Type: PROCEDURE; Name: Smear microscopy; Assigned to Arm(s): Sputum smear microscopy
D: Arm Label: Antiretroviral therapy, tuberculosis; Type: N/A; Interventions: N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial to Evaluate the Impact of Using a Point-of-care Urine LAM Strip Test for TB Diagnosis Amongst Hospitalized HIV-infected Patients in Resource-poor Settings
Brief Summary: The novel urine LAM point-of-care strip test offers potential clinical utility to improve TB diagnosis in HIV co-infected patients. Urine LAM strip test performance improves with increasing illness severity and more advanced immunosuppression, thus offering the greatest potential utility in hospitalised HIV-infected patients with advanced immunosuppression (CD4 cell count less than 200). However, in the context of high rates of empiric treatment and the availability of other novel TB diagnostics, the clinical impact of the urine LAM strip test is unknown. This study will investigate the impact of the urine LAM strip test. The study hypothesis is that the urine LAM strip test, when combined with standard TB diagnostics (smear microscopy and culture) will significantly improve TB treatment-related outcomes (TB-related mortality, morbidity and length of hospital stay) in HIV-infected hospitalized patients when compared to standard TB diagnostics alone.


Options:
A: Arm Label: LAM plus standard care; Type: EXPERIMENTAL; Interventions: Device: Urine LAM strip test | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Urine LAM strip test; Assigned to Arm(s): LAM plus standard care
B: Arm Label: Centralised Xpert®Ultra testing; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Xpert Ultra Point of Care testing; Type: ACTIVE_COMPARATOR; Interventions: Diagnostic Test: Xpert Ultra Point of Care testing | Intervention Type: DIAGNOSTIC_TEST; Name: Xpert Ultra Point of Care testing; Assigned to Arm(s): Xpert Ultra Point of Care testing
C: Intervention Type: OTHER; Name: No Intervention; Assigned to Arm(s): N/A
D: Arm Label: PLHIV Centralised Xpert Ultra; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: PLHIV Point of Care Xpert Ultra; Type: ACTIVE_COMPARATOR; Interventions: Diagnostic Test: PLHIV Point of Care Xpert Ultra | Arm Label: PLHIV Centralised Xpert VL; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: PLHIV Point of Care Xpert VL; Type: ACTIVE_COMPARATOR; Interventions: Diagnostic Test: PLHIV Point of Care Xpert VL | Intervention Type: DIAGNOSTIC_TEST; Name: PLHIV Point of Care Xpert Ultra; Assigned to Arm(s): PLHIV Point of Care Xpert Ultra | Intervention Type: DIAGNOSTIC_TEST; Name: PLHIV Point of Care Xpert VL; Assigned to Arm(s): PLHIV Point of Care Xpert VL

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial to Evaluate the Impact of Using a Point-of-care Urine LAM Strip Test for TB Diagnosis Amongst Hospitalized HIV-infected Patients in Resource-poor Settings
Brief Summary: The novel urine LAM point-of-care strip test offers potential clinical utility to improve TB diagnosis in HIV co-infected patients. Urine LAM strip test performance improves with increasing illness severity and more advanced immunosuppression, thus offering the greatest potential utility in hospitalised HIV-infected patients with advanced immunosuppression (CD4 cell count less than 200). However, in the context of high rates of empiric treatment and the availability of other novel TB diagnostics, the clinical impact of the urine LAM strip test is unknown. This study will investigate the impact of the urine LAM strip test. The study hypothesis is that the urine LAM strip test, when combined with standard TB diagnostics (smear microscopy and culture) will significantly improve TB treatment-related outcomes (TB-related mortality, morbidity and length of hospital stay) in HIV-infected hospitalized patients when compared to standard TB diagnostics alone.


Options:
A: Arm Label: LAM plus standard care; Type: EXPERIMENTAL; Interventions: Device: Urine LAM strip test | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Urine LAM strip test; Assigned to Arm(s): LAM plus standard care
B: Arm Label: Novel; Type: EXPERIMENTAL; Interventions: Procedure: GeneXpert MTB/RIF assay, Procedure: Smear microscopy | Arm Label: Standard; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Smear microscopy | Intervention Type: PROCEDURE; Name: GeneXpert MTB/RIF assay; Assigned to Arm(s): Novel | Intervention Type: PROCEDURE; Name: Smear microscopy; Assigned to Arm(s): Novel, Standard
C: Arm Label: Urgent ART; Type: EXPERIMENTAL; Interventions: Other: Urgent ART | Arm Label: Early ART; Type: ACTIVE_COMPARATOR; Interventions: Other: Early ART | Intervention Type: OTHER; Name: Urgent ART; Assigned to Arm(s): Urgent ART | Intervention Type: OTHER; Name: Early ART; Assigned to Arm(s): Early ART
D: Intervention Type: DEVICE; Name: Alere "Determine" lateral-flow urine lipoarabinomannan assay; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Alere "Clearview" ELISA urine LAM assay; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Cepheid Xpert MTB/Rif assay; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial to Evaluate the Impact of Using a Point-of-care Urine LAM Strip Test for TB Diagnosis Amongst Hospitalized HIV-infected Patients in Resource-poor Settings
Brief Summary: The novel urine LAM point-of-care strip test offers potential clinical utility to improve TB diagnosis in HIV co-infected patients. Urine LAM strip test performance improves with increasing illness severity and more advanced immunosuppression, thus offering the greatest potential utility in hospitalised HIV-infected patients with advanced immunosuppression (CD4 cell count less than 200). However, in the context of high rates of empiric treatment and the availability of other novel TB diagnostics, the clinical impact of the urine LAM strip test is unknown. This study will investigate the impact of the urine LAM strip test. The study hypothesis is that the urine LAM strip test, when combined with standard TB diagnostics (smear microscopy and culture) will significantly improve TB treatment-related outcomes (TB-related mortality, morbidity and length of hospital stay) in HIV-infected hospitalized patients when compared to standard TB diagnostics alone.


Options:
A: Intervention Type: DEVICE; Name: Alere "Determine" lateral-flow urine lipoarabinomannan assay; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Alere "Clearview" ELISA urine LAM assay; Assigned to Arm(s): N/A
B: Arm Label: Xpert MTB/RIF; Type: EXPERIMENTAL; Interventions: Procedure: Xpert MTB/RIF assay | Arm Label: Sputum smear microscopy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Smear microscopy | Intervention Type: PROCEDURE; Name: Xpert MTB/RIF assay; Assigned to Arm(s): Xpert MTB/RIF | Intervention Type: PROCEDURE; Name: Smear microscopy; Assigned to Arm(s): Sputum smear microscopy
C: Arm Label: LAM plus standard care; Type: EXPERIMENTAL; Interventions: Device: Urine LAM strip test | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Urine LAM strip test; Assigned to Arm(s): LAM plus standard care
D: Intervention Type: DEVICE; Name: Alere "Determine" lateral-flow urine lipoarabinomannan assay; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Alere "Clearview" ELISA urine LAM assay; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Cepheid Xpert MTB/Rif assay; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Controlled Trial to Evaluate the Impact of Using a Point-of-care Urine LAM Strip Test for TB Diagnosis Amongst Hospitalized HIV-infected Patients in Resource-poor Settings
Brief Summary: The novel urine LAM point-of-care strip test offers potential clinical utility to improve TB diagnosis in HIV co-infected patients. Urine LAM strip test performance improves with increasing illness severity and more advanced immunosuppression, thus offering the greatest potential utility in hospitalised HIV-infected patients with advanced immunosuppression (CD4 cell count less than 200). However, in the context of high rates of empiric treatment and the availability of other novel TB diagnostics, the clinical impact of the urine LAM strip test is unknown. This study will investigate the impact of the urine LAM strip test. The study hypothesis is that the urine LAM strip test, when combined with standard TB diagnostics (smear microscopy and culture) will significantly improve TB treatment-related outcomes (TB-related mortality, morbidity and length of hospital stay) in HIV-infected hospitalized patients when compared to standard TB diagnostics alone.


Options:
A: Arm Label: LAM plus standard care; Type: EXPERIMENTAL; Interventions: Device: Urine LAM strip test | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Urine LAM strip test; Assigned to Arm(s): LAM plus standard care
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Interventional; Type: EXPERIMENTAL; Interventions: Diagnostic Test: Xpert MTB/RIF Ultra (Ultra) | Intervention Type: DIAGNOSTIC_TEST; Name: Xpert MTB/RIF Ultra (Ultra); Assigned to Arm(s): Interventional
C: Arm Label: Smear; Type: ACTIVE_COMPARATOR; Interventions: Other: Smear | Arm Label: GeneXpert; Type: EXPERIMENTAL; Interventions: Other: Xpert | Intervention Type: OTHER; Name: Xpert; Assigned to Arm(s): GeneXpert | Intervention Type: OTHER; Name: Smear; Assigned to Arm(s): Smear
D: Arm Label: Xpert MTB/RIF®, Determine TB LAM, Chest X-ray; Type: EXPERIMENTAL; Interventions: Device: Xpert MTB/RIF®, Determine TB LAM, Chest X-ray, Drug: ART (Atripla, Truvada, Efavirenz, Combivir), Drug: Rifampin, isoniazid, pyrazinamide, ethambutol | Arm Label: Rifampin, isoniazid, pyrazinamide, ethambutol; Type: EXPERIMENTAL; Interventions: Drug: ART (Atripla, Truvada, Efavirenz, Combivir), Drug: Rifampin, isoniazid, pyrazinamide, ethambutol | Intervention Type: DEVICE; Name: Xpert MTB/RIF®, Determine TB LAM, Chest X-ray; Assigned to Arm(s): Xpert MTB/RIF®, Determine TB LAM, Chest X-ray | Intervention Type: DRUG; Name: ART (Atripla, Truvada, Efavirenz, Combivir); Assigned to Arm(s): Rifampin, isoniazid, pyrazinamide, ethambutol, Xpert MTB/RIF®, Determine TB LAM, Chest X-ray | Intervention Type: DRUG; Name: Rifampin, isoniazid, pyrazinamide, ethambutol; Assigned to Arm(s): Rifampin, isoniazid, pyrazinamide, ethambutol, Xpert MTB/RIF®, Determine TB LAM, Chest X-ray

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pregnancy and EARly Lifestyle Improvement Study
Brief Summary: The investigators propose to conduct a randomized controlled trial in 200 overweight/obese pregnant women and their offspring. The prenatal intervention will emphasize improving diet and physical activity. The lifestyle intervention will be delivered within an empowerment theoretical framework through a combination of group sessions, individual counseling, and by monitoring compliance to diet and physical activity to further tailor the intervention. The post-partum intervention sessions will include mothers and their offspring and will focus on breastfeeding, improving physical activity and quality of the diet and feeding practices through the first post-partum year. As part of routine prenatal care, participants in both the control and intervention arms will be given health-related advice. Since the majority of participants are expected to be eligible for the Women, Infants and Children (WIC) program, both groups will also receive assistance through WIC as per their routine policies. Our primary outcome is Gestational Weight Gain (GWG). The major secondary outcome of interest is infant BMI z-score at 12 months of age, and the investigators will also be evaluating several metabolic outcomes in mothers and infants.


Options:
A: Arm Label: Lifestyle and nutrition control group; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Lifestyle intervention group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Lifestyle intervention group | Intervention Type: BEHAVIORAL; Name: Lifestyle intervention group; Assigned to Arm(s): Lifestyle intervention group
B: Arm Label: Nutritional counseling & self blood glucose monitoring; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: nutritional counseling, Behavioral: self blood glucose monitoring | Arm Label: No treatment; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: nutritional counseling; Assigned to Arm(s): Nutritional counseling & self blood glucose monitoring | Intervention Type: BEHAVIORAL; Name: self blood glucose monitoring; Assigned to Arm(s): Nutritional counseling & self blood glucose monitoring
C: Arm Label: control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle | Intervention Type: BEHAVIORAL; Name: Lifestyle; Assigned to Arm(s): Intervention
D: Arm Label: Enhanced Standard Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced standard care | Arm Label: Intensive lifestyle intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive lifestyle intervention | Intervention Type: BEHAVIORAL; Name: Enhanced standard care; Assigned to Arm(s): Enhanced Standard Care | Intervention Type: BEHAVIORAL; Name: Intensive lifestyle intervention; Assigned to Arm(s): Intensive lifestyle intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: N/A
Brief Summary: Selective cannulation of common bile duct (CBD) by insertion of a guide-wire seems to be associated with fewer complications and post-ERCP (Endoscopic retrograde cholangiopancreatography) pancreatitis (PEP) rate than the conventional biliary tree access with cannulotome (CT-25 Cook Medical) with contrast injection even if results are conflicting. the aim of our study is to test a new guide-wire (loop-tip wire), with a loop in the tip, for the prevention of PEP and biliary tree access, in PEP high-risk patients.


Options:
A: Arm Label: 0.035 guidewire; Type: ACTIVE_COMPARATOR; Interventions: Device: Conventional 0.035 guidewire | Arm Label: Olympus Visiglide 0.025 guidewire; Type: ACTIVE_COMPARATOR; Interventions: Device: Olympus Visiglide 0.025 guidewire | Intervention Type: DEVICE; Name: Conventional 0.035 guidewire; Assigned to Arm(s): 0.035 guidewire | Intervention Type: DEVICE; Name: Olympus Visiglide 0.025 guidewire; Assigned to Arm(s): Olympus Visiglide 0.025 guidewire
B: Intervention Type: PROCEDURE; Name: Double guide wire technique; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Standard bile duct cannulation; Assigned to Arm(s): N/A
C: Arm Label: A (NS+Placebo); Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal Saline, Drug: Placebo | Arm Label: B (NS+IND); Type: ACTIVE_COMPARATOR; Interventions: Drug: Indomethacin, Drug: Normal Saline | Arm Label: C (LR+Placebo); Type: ACTIVE_COMPARATOR; Interventions: Drug: Lactated Ringer's Solution, Drug: Placebo | Arm Label: D (LR+IND); Type: EXPERIMENTAL; Interventions: Drug: Indomethacin, Drug: Lactated Ringer's Solution | Intervention Type: DRUG; Name: Indomethacin; Assigned to Arm(s): B (NS+IND), D (LR+IND) | Intervention Type: DRUG; Name: Lactated Ringer's Solution; Assigned to Arm(s): C (LR+Placebo), D (LR+IND) | Intervention Type: DRUG; Name: Normal Saline; Assigned to Arm(s): A (NS+Placebo), B (NS+IND) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A (NS+Placebo), C (LR+Placebo)
D: Arm Label: loop-tip arm; Type: EXPERIMENTAL; Interventions: Device: Loop-tip wire (Cook Medical) for the cannulation of the CBD | Arm Label: Control arm; Type: ACTIVE_COMPARATOR; Interventions: Device: Cannulotome CT-25mm Cook Medical | Intervention Type: DEVICE; Name: Loop-tip wire (Cook Medical) for the cannulation of the CBD; Assigned to Arm(s): loop-tip arm | Intervention Type: DEVICE; Name: Cannulotome CT-25mm Cook Medical; Assigned to Arm(s): Control arm

Answer: D